|Name||PRICE||MARKET CAPITALIZATION||PRICE TO EARNINGS RATIO||DIVIDEND YIELD||SYMBOL||EXCHANGE||PRICE PERCENT DIFFERENCE||YEAR TO DATE PRICE PERCENT DIFFERENCE||5 YEAR CHART||1 YEAR CHART|
Intercept Pharmaceuticals Inc [ICPT]
$86.15 1.21 (1.42%)
Market Cap 2.78 Billion
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. Intercept owns worldwide rights to OCA outside of China, where it has licensed out the product to Sumitomo Dainippon Pharma.
EPS -3.03 P/E Ratio 0.00
Previous Earnings Thu, Feb 28, 2019
Pay Date --
This list of trending stocks may change throughout the trading day.